Phathom Pharmaceuticals, Inc.
Financials
Valuation Metrics
Phathom Pharmaceuticals, Inc.'s Market Cap is $472M. At end of 2025 it was $1.21B. Ranked #2750 of 3,116 in US market (top 88%), #1203 of 1,472 on NASDAQ (top 82%), #218 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $472M | US#2,750/3,116 Sec#218/265 |
| Revenue | $275M | US#2,503/3,116 Sec#104/265 |
| Net Income | $-69M | US—/3,116 Sec—/265 |
| Total Assets | $345M | US#2,886/3,116 Sec#200/265 |
| Net Assets | $-348M | US#3,000/3,116 Sec#260/265 |
| Employees | 371 | US#2,349/3,116 Sec#98/265 |
| Value | ||
| P/S | 1.72x | US#1,301/3,116 Sec#29/265 |
| FCF Yield | -4.37% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -20.03% | US#2,881/3,116 Sec#157/265 |
| Op. Margin | -9.26% | US#2,557/3,116 Sec#97/265 |
| Revenue Growth | 86.75% | US#85/3,116 Sec#30/265 |
| Financial Health | ||
| Total Debt | $2M | US#2,289/3,116 Sec#99/265 |
| FCF | $-21M | US#2,484/3,116 Sec#105/265 |
| Cash | $185M | US#1,800/3,116 Sec#116/265 |
| Current Ratio | 1.76x | US#1,279/3,116 Sec#222/265 |
| Performance | ||
| 1Y Return | -56.35% | US#2,918/3,116 Sec#241/265 |
| 1M Return | -14.52% | US#2,772/3,116 Sec#224/265 |
| From 52W High | -67.70% | US#2,939/3,116 Sec#233/265 |
| 1Y MDD | -68.25% | US#2,907/3,116 Sec#235/265 |
| Trading | ||
| Volume | 2,798,401 shares | US#498/3,116 Sec#42/265 |
| Trading Value | $16M | US#1,791/3,116 Sec#137/265 |
| Per Share | ||
| EPS | $-0.87 | US—/3,116 Sec—/265 |
| BPS | $-4.36 | US—/3,116 Sec—/265 |
Company Info
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.